The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

Overview

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Full Title of Study: “The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Primary Purpose: Diagnostic
  • Masking: None (Open Label)
• Study Primary Completion Date: December 2022

Interventions

• Drug: methylphenidate, fluoxetin, risperidone
  • first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Arms, Groups and Cohorts

• Experimental: 1

Clinical Trial Outcome Measures

Primary Measures

• Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments
  • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

• chromosomal deletion proven by FISH examination Exclusion Criteria:

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • The Chaim Sheba Medical Center
• Provider of Information About this Clinical Study
  • Principal Investigator: Prof. Doron Gothelf, Principal Investigator – The Chaim Sheba Medical Center
• Overall Contact(s)
  • Doron Gothelf, MD, 972-03-5302663, gothelf@post.tau.ac.il